Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Cancer and Oncology
-
3. Latest advances in the development of CAR & TCR T-cell treatments for solid tumours
- Dr. Else Marit Inderberg
-
4. Mode of action of T cells engineered with CAR or TCR for cancer treatment
- Prof. Sebastian Kobold
-
5. Immunotherapy: insights from advanced disease
- Dr. Sara M. Tolaney
-
6. Recent advances in the field of non-coding RNAs in cancer
- Prof. George Calin
- Dr. Maitri Shah
-
7. How tumor-microenvironment interactions drive or inhibit metastasis
- Prof. Isaac P. Witz
-
8. A novel cancer therapy to stimulate oncogenic ERK signalling
- Prof. Reiko Sugiura
-
9. MRD-driven multiple myeloma treatment: next step forward
- Prof. Ola Landgren
-
11. Germinal centre lymphomas: advances in diagnostic and therapeutic intervention
- Dr. Koorosh Korfi
- Prof. Jude Fitzgibbon
-
12. Immunotherapy in lung cancer
- Dr. Mark M. Awad
-
13. Preservation of fertility in cancer patients: the impact of chemotherapy
- Prof. Kutluk H. Oktay
-
15. Solution proposed to a 2000 year old problem in oncology
- Dr. Michael Retsky
- Clinical Practice
-
16. Stillbirth: diagnosis, investigation and aftercare
- Prof. Alexander E. P. Heazell
-
17. Analyzing the medical relevance of skin care trends
- Prof. Zoe Draelos
-
18. Genetic counseling: preconception, prenatal, perinatal
- Prof. Aubrey Milunsky
-
19. The past, present & future of ANA testing: history and challenges of ANA
- Prof. Marvin J. Fritzler
-
20. The past, present & future of ANA testing: changing bandwidth and future of ANA
- Prof. Marvin J. Fritzler
-
22. Mitochondrial diseases: an update
- Dr. Ayesha Saleem
-
23. Hemophilia A
- Dr. Snejana Krassova
-
26. Recent advances in diagnosis and interventions in ophthalmology
- Dr. Rebecca Kaye
- Prof. Andrew Lotery
- Gastroenterology
-
27. Building implantable human liver tissue from pluripotent stem cells
- Prof. David C. Hay
-
28. Microbiome therapies to treat gastrointestinal diseases
- Dr. Patricia Bloom
-
29. Drug-induced liver injury: importance, epidemiology, and mechanisms of DILI
- Prof. James H. Lewis
-
30. Drug-induced liver injury: risk factors and drug development in DILI
- Prof. James H. Lewis
-
31. Drug-induced liver injury: HDS, diagnosing, treating and preventing DILI
- Prof. James H. Lewis
-
32. An update on the multiple faces of celiac disease
- Prof. Aaron Lerner
- Immunology
-
33. Drug allergy: new knowledge
- Prof. Mariana C. Castells
-
34. Biologics as a treatment strategy in food allergy
- Prof. Sayantani B. Sindher
-
35. B cells at the crossroads of autoimmune diseases
- Dr. Xiang Lin
-
36. Studying immune responses “one cell at a time”
- Dr. Mir-Farzin Mashreghi
-
37. Mathematical modeling in immunology
- Prof. Ruy M. Ribeiro
-
38. Therapeutic antibody development
- Prof. Dr. Katja Hanack
-
39. Understanding treatment coverage in mass drug administrations
- Dr. Margaret Baker
-
40. The thymus and T cell development: a primer
- Prof. Georg Holländer
- Infectious Diseases
-
42. The Global Virus Network: collaboration to address pandemic and regional threats
- Prof. Sten H. Vermund
-
43. New concepts in the management of CAP: a focus on severe illness - treatment and therapies
- Prof. Michael S. Niederman
-
44. New concepts in the management of CAP: a focus on severe illness - MRSA and MDR pathogens
- Prof. Michael S. Niederman
-
45. CRISPR-based suppression drives for vector control
- Prof. Andrea Crisanti
-
46. HIV cure: harnessing innate and adaptive strategies
- Prof. Luis Montaner
- Cardiovascular, Metabolism & Nutrition
-
47. Cow’s milk allergy: the future
- Dr. Carina Venter
-
48. Cow's milk allergy: management
- Dr. Carina Venter
-
49. Moving from GWAS hits to functional variants
- Prof. Steve Humphries
-
50. X-linked hypophosphataemia: genetics, diagnosis and management
- Prof. Thomas O. Carpenter
-
51. What is new in type 1 diabetes?
- Prof. Åke Lernmark
-
52. Current concepts for the management of patients with osteoporosis
- Dr. Michael Lewiecki
-
53. Antibodies to control or prevent type 1 diabetes
- Dr. Robert Hilbrands
-
54. Peptide YY (PYY) in obesity and diabetes
- Dr. Nigel Irwin
- Microbiology
-
55. Vaccines and the fight against antimicrobial resistance 1
- Dr. Annaliesa S. Anderson
-
56. Vaccines and the fight against antimicrobial resistance 2
- Dr. Annaliesa S. Anderson
-
57. Vaccines as a weapon against antibiotic resistance
- Dr. Pumtiwitt McCarthy
-
58. PathoLive: pathogen detection while sequencing
- Dr. Simon Tausch
-
60. Successes and failures with vaccines
- Prof. Stanley Plotkin
-
61. Immunology, the microbiome and future perspectives
- Prof. Sheena Cruickshank
-
62. Impact of the HPV vaccine programme – a changing landscape
- Dr. Kevin Pollock
- Neurology and Neuroscience
-
63. Advances in the diagnosis and treatment of tardive dyskinesia
- Prof. Emeritus Stanley N. Caroff
-
64. Cellular therapies for neurological Injuries: bioreactors, potency, and coagulation
- Prof. Charles S. Cox, Jr.
-
65. Cardiovascular involvement in Parkinson’s disease
- Dr. David S. Goldstein
-
66. Molecular brain imaging (PET) in diseases with dementia
- Prof. Karl Herholz
-
67. Current thinking in pain medicine and some thoughts on back pain
- Dr. Nick Hacking
-
68. Bioelectronic medicine: immunomodulation by vagus nerve stimulation
- Prof. Paul Peter Tak
-
69. Developments & future directions in the management of chronic pain
- Prof. Simon Haroutounian
-
70. Deep Brain Stimulation (DBS) neuromodulation for Schizophrenia
- Prof. Judith Gault
-
71. Parkinson’s at 200 years: an update on Parkinson’s research in 2017
- Prof. Patrick A. Lewis
-
72. Alzheimer's disease: where are we up to?
- Prof. John Hardy
- Pharmaceutical Sciences
-
73. Pharmacokinetics, -dynamics and dosing considerations in children
- Prof. Dr. Karel Allegaert
-
74. Why in vitro permeation test – and not in vivo?
- Prof. Howard Maibach
-
75. The future of plasma-derived medicinal products (PDMP)
- Dr. Daniele Focosi
-
76. RNA therapeutics: clinical applications and methods of delivery
- Prof. John P. Cooke
-
77. Recent advances in the development of gene delivery technologies
- Dr. Takis Athanasopoulos
-
78. Preclinical translation of mesenchymal stem cell therapies
- Dr. Peter Childs
-
79. Modulating gene expression to treat diseases
- Dr. Navneet Matharu
-
80. Accelerating drug discovery with machine learning and AI
- Dr. Olexandr Isayev
-
81. AI and big data in drug discovery
- Mr. Ed Addison
-
82. Emerging big data in medicinal chemistry: promiscuity analysis as an example
- Prof. Dr. Jürgen Bajorath
- Dr. Ye Hu
-
83. Binding kinetics in drug discovery
- Dr. Rumin Zhang
-
84. Modeling of antibody-drug conjugate pharmacokinetics
- Dr. Dhaval K. Shah
-
85. Antibody engineering: beginnings to bispecifics and beyond
- Dr. Ian Wilkinson
-
86. Current challenges in the design of antibody-drug conjugates
- Prof. L. Nathan Tumey
-
87. Inorganic nanostructured interfaces for therapeutic delivery
- Prof. Tejal Desai
-
88. Latest development in therapy-related autophagy research
- Dr. Vignir Helgason
- Respiratory Diseases
-
89. Respiratory syncytial virus vaccination
- Prof. Peter Openshaw
-
90. Advances in gene therapy for respiratory diseases 1
- Prof. John F. Engelhardt
-
91. Advances in gene therapy for respiratory diseases 2
- Prof. John F. Engelhardt
-
92. Asthma
- Prof. William Busse
- Dr. Amanda McIntyre
-
93. New drugs for asthma
- Prof. Peter Barnes
-
94. CompEx asthma: a novel composite exacerbation endpoint
- Dr. Carla A. Da Silva
-
95. Updates in chronic obstructive pulmonary disease (COPD)
- Dr. Omar S. Usmani
Printable Handouts
Navigable Slide Index
- Introduction
- DBS for schizophrenia
- Schizophrenia, disease course
- Schizophrenia, unmet needs
- DBS inclusion criteria
- Surgery in schizophrenia
- Dopamine D2 receptor & schizophrenia
- The striatum & schizophrenia
- Cortico-basal ganglia-thalamo-cortical circuit
- Mechanistic models implicating DBS targets
- The hippocampus and medial septal nucleus
- Ventral capsule/Ventral striatum/NAc
- Ventral tegmental area
- Subgenual cingulate white matter tract
- DBS targeting the limbic region of SNr or STN
- The associative striatum
- Globus pallidus interna
- Patients with schizophrenia treated with DBS
- First report of bilateral DBS targeting the NAc
- DBS risks by target
- General risks for DBS
- Risks vs. Benefits
- Ethics of DBS
- Optimal clinical trial design
- Summary
- References
Topics Covered
- General characteristics of schizophrenia
- Unmet needs in patients
- Amenability of the patient population to DBS
- Comparing schizophrenia to Parkinson’s disease, essential tremor & dystonia
- Targets and risks of DBS
- When risks outweigh benefits of DBS
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Gault, J. (2018, June 28). Deep Brain Stimulation (DBS) neuromodulation for Schizophrenia [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 31, 2024, from https://doi.org/10.69645/IDTH5773.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Judith Gault, Grant/Research Support (Principal Investigator): Brain and Behavior Research Foundation; NARSAD Independent Investigator Grants
A selection of talks on Neurology
Transcript
Please wait while the transcript is being prepared...
0:00
Hi, I'm Judy Gault.
I'm a Research Associate Professor,
engaged in schizophrenia research at
the University of Colorado in the Departments of Neurosurgery and Psychiatry.
Today's presentation is on
deep brain stimulation and its use for neuromodulation in schizophrenia,
specifically, treatment refractory schizophrenia.
0:25
So, the overview for my presentation for
deep brain stimulation for schizophrenia is to first,
go over the general characteristics of schizophrenia.
Then, discuss the unmet needs in patients with schizophrenia,
and in the treatment refractory population.
Then, discuss whether this patient population
is actually amenable to deep brain stimulation.
Then, we'll ask the question of whether schizophrenia,
is a circuit disorder like Parkinson's disease,
and a central tremor, and dystonia.
These are disorders that are currently being treated with deep brain stimulation,
and we'll ask the question,
is schizophrenia circuit disorder like these
and therefore amenable to deep brain stimulation?
If so, what are the targets?
What are the risks?
We need to discuss the ethics and when do the benefits outweigh the risks.
The image is of a patient who actually has a deep brain stimulation unit implanted
and you can see what it entails in terms of the leads
and the connection to a neuromodulation pulse generator.
1:39
Schizophrenia has a lifetime prevalence of 1 percent.
Most people are familiar with psychosis,
the hallmark symptom of schizophrenia.
But in addition patients may experience disabling negative symptoms,
like being unable to initiate or sustain simple daily activities.
Furthermore, cognition and cognitive deficits are a core feature of schizophrenia.
The majority of patients demonstrate a relapsing and
remitting course of psychotic symptoms where
development of a closed loop deep brain stimulation system that
adapts to symptoms severity would be particularly beneficial.
Antipsychotics are the gold standard for treatment of psychosis.
Examples include Clozapine and Risperidone.
Nonetheless, about 33 percent of patients continue to
experience severe psychotic symptoms despite antipsychotic treatment,
and have less than 20 to 30 percent improvement in symptoms with antipsychotic treatment.
You can see in the slide here,
the colored bar across the top,
that patients initially try out
various antipsychotic medications and then they'll
relapse and are often changed to other medications.
Another reason for changing antipsychotic would be
the presence of side effects that are intolerable.
Also shown is a threshold for hospitalization.
You can see where the black line indicating psychotic symptoms.
When it gets high,
indicating acute relapse of psychosis,
that those would be points when the patient may be hospitalized.
The patient goes through a progressive stage of illness where relapse is common.
Maybe even once a year,
there may be multiple hospitalizations and multiple antipsychotics may be tried.
The symptom threshold shown in the slide can be changed depending on the person.
So, a person with treatment refractory schizophrenia
has actually shown here where the majority of
the time the patient is actually
experiencing psychotic symptoms despite treatment with anti psychotics.
A person who is very responsive to antipsychotic treatment,
the symptom threshold line would be increased and
most of the time their symptoms wouldn't break through.
During the residual part of the illness,
the acute psychotic episodes become more widely spaced and person
becomes more familiar with dealing with their chronic illness and their support groups.
Their family members, and their psychiatrist,
and team members at
the mental health facility where they may be seen are more familiar with
the routine of what an acute psychotic relapse looks like and how to intervene.
So, while psychosis in general may improve during the course of illness,
the negative and cognitive symptoms, if present,
are more constant and fluctuate less acutely.
So, it's worth noting that patients with schizophrenia are often
diagnosed as young adults and go through this progressive stage of illness,
marked by frequent relapses,
and often requiring hospitalization and trying multiple different antipsychotics.
Then, during the residual stage of illness,
the patient relapses less often.
But the point is that,
it's a chronic illness and the disease burden continues throughout life and so
an early intervention that was effective would significantly impact the patient's life.
Furthermore, it's worth noting that even in treatment responsive patients,
antipsychotics do not control negative or cognitive symptoms.
Antipsychotics are effective at treating only the positive symptoms.
So, this slide goes over the many unmet needs of patients with schizophrenia,